Botulinum toxin a detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: A single-blind study

Urology

Volumn 81, Issue 5, 2013, Pages 1052-1057

  Schulte Baukloh, Heinrich ^a   Priefert, Judith ^a   Knispel, Helmut H ^a   Lawrence, Gary W ^b   Miller, Kurt ^a   Neuhaus, Jochen ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DUBLIN CITY UNIVERSITY   (Ireland)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DIAMINOBENZIDINE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X3 RECEPTOR;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BLADDER COMPLIANCE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR MUSCLE; DOWN REGULATION; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; BOTULINUM TOXINS, TYPE A; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS; MALE; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, PURINERGIC P2X2; RECEPTORS, PURINERGIC P2X3; SINGLE-BLIND METHOD; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS; YOUNG ADULT;

EID: 84876680021     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.12.021     Document Type: Article

References (30)

1. M. Stöhrer, B. Schurch, and G. Kramer Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 18 1999 401 402
2. A. Coelho, P. Dinis, and R. Pinto Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder Eur Urol 57 2010 884 890
3. A. Apostolidis, P. Dasgupta, and P. Denys Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report Eur Urol 55 2009 100 119
4. M. Khera, G.T. Somogyi, and S. Kiss Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury Neurochem Int 45 2004 987 993
5. D.E. Rapp, K.W. Turk, and G.T. Bales Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder J Urol 175 2006 1138 1142
6. K.J. Mansfield, L. Liu, and F.J. Mitchelson Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing Br J Pharmacol 144 2005 1089 1099
7. P. Wang, G.R. Luthin, and M.R. Ruggieri Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins J Pharmacol Exp Ther 273 1995 959 966
8. S.S. Hegde, A. Choppin, and D. Bonhaus Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo Br J Pharmacol 120 1997 1409 1418
9. M. Matsui, D. Motomura, and T. Fujikawa Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable J Neurosci 22 2002 10627 10632
10. Y. Sun, and T.C. Chai Role of Purinergic Signaling in Voiding Dysfunction Curr Bladder Dysfunct Rep 5 2010 219 224
11. J. Pannek, S. Janek, and F. Sommerer Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study Spinal Cord 47 2009 561 564
12. A. Apostolidis, R. Popat, and Y. Yiangou Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity J Urol 174 2005 977 982 [discussion: 982-983]
13. S.H. Lu, W.C. Groat, and A.T. Lin Evaluation of purinergic mechanism for the treatment of voiding dysfunction: a study in conscious spinal cord-injured rats J Chin Med Assoc 70 2007 439 444
14. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
15. H. Schulte-Baukloh, T. Michael, and B. Sturzebecher Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder Eur Urol 44 2003 139 143
16. J. Neuhaus, H. Schulte-Baukloh, and J.U. Stolzenburg Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) World J Urol 30 2012 693 700
17. C.R. Ahsan, G. Hajnoczky, and A.B. Maksymowych Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells J Pharmacol Exp Ther 315 2005 1028 1035
18. H. Schulte-Baukloh, T.H. Zurawski, and H.H. Knispel Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment BJU Int 100 2007 1075 1080
19. F.J. Ehlert, M.T. Griffin, and D.M. Abe The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder J Pharmacol Exp Ther 313 2005 368 378
20. A.S. Braverman, and M.R. Ruggieri Sr. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2 Am J Physiol Regul Integr Comp Physiol 285 2003 R701 R708
21. M.A. Pontari, A.S. Braverman, and M.R. Ruggieri Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction Am J Physiol Regul Integr Comp Physiol 286 2004 R874 R880
22. S.N. Datta, A. Roosen, and A. Pullen Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration J Urol 184 2010 2578 2585
23. E. Shapiro, M.J. Seller, and H. Lepor Altered smooth muscle development and innervation in the lower genitourinary and gastrointestinal tract of the male human fetus with myelomeningocele J Urol 160 1998 1047 1053 discussion: 1079
24. G.N. Sibley A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit J Physiol 354 1984 431 443
25. M. Bayliss, C. Wu, and D. Newgreen A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders J Urol 162 1999 1833 1839
26. B.A. O'Reilly, A.H. Kosaka, and G.F. Knight P2X receptors and their role in female idiopathic detrusor instability J Urol 167 2002 157 164
27. C.M. Brady, A. Apostolidis, and Y. Yiangou P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin Eur Urol 46 2004 247 253
28. M. Yoshida, K. Miyamae, and H. Iwashita Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging Urology 63 suppl 3A 2004 17 23
29. R.A. Harvey, D.E. Skennerton, and D. Newgreen The contractile potency of adenosine triphosphate and ecto-adenosine triphosphate activity in guinea pig detrusor and detrusor from patients with a stable, unstable or obstructed bladder J Urol 168 2002 1235 1239
30. G.W. Lawrence, K.R. Aoki, and J.O. Dolly Excitatory cholinergic and purinergic signalling in bladder are equally susceptible to botulinum neurotoxin A consistent with co-release of transmitters from efferent fibres J Pharmacol Exp Ther 334 2010 1080 1086